Medication for alcohol dependence: the silver bullet?

Furmark T Appel L Michelgard A Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry 2005; 58(2):132–42.

Heilig M Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007; 30(8):399–406.

Richardson HN Zhao Y Fekete EM MPZP: A novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav 2008; 88(4):497–510.

Ji D Gilpin NW Richardson HN Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19(1):1–12.

Holmes A Heilig M Rupniak NMJ Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24(11):580–8.

Kramer MS Cutler N Feighner J Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281(5383):1640–5.

Knabl J Witschi R Hösl K Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008; 451(7176):330–4.

Patil ST Zhang L Martenyi F Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med 2007; 13:1102–7.

Addolorato G Leggio L Ferrulli A Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcoholdependent patients with liver cirrhosis: randomised, doubleblind controlled study. Lancet 2007; 370(9603):1915–22.

Spanagel R Kiefer F. Drugs for relapse prevention of alcoholism – 10 years of progress. Trends Pharmacol Sci 2008; 29(3):109–15.

Luty J. What works in alcohol use disorders? Adv Psychiatr Treat 2008;12:13–22.

UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 2005; 331(7516):541.